S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
NASDAQ:TGTX

TG Therapeutics - TGTX Stock Forecast, Price & News

$8.31
+0.79 (+10.51%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.62
$8.53
50-Day Range
$3.74
$8.31
52-Week Range
$3.48
$35.94
Volume
4.23 million shs
Average Volume
2.91 million shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25

TG Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
155.7% Upside
$21.25 Price Target
Short Interest
Bearish
15.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.92mentions of TG Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.77) to ($1.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

573rd out of 1,135 stocks

Pharmaceutical Preparations Industry

290th out of 557 stocks

TGTX stock logo

About TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Analysts Set New Price Targets

TGTX has been the topic of several research reports. StockNews.com upgraded TG Therapeutics to a "sell" rating in a research note on Friday, June 17th. B. Riley lowered their price target on shares of TG Therapeutics from $23.00 to $17.00 and set a "buy" rating on the stock in a research note on Monday, June 13th. Cantor Fitzgerald reissued an "overweight" rating on shares of TG Therapeutics in a research report on Monday, May 9th. Bank of America assumed coverage on TG Therapeutics in a report on Friday, May 20th. They issued an "underperform" rating for the company. Finally, HC Wainwright dropped their target price on TG Therapeutics from $68.00 to $19.00 and set a "buy" rating on the stock in a report on Monday, April 18th. Three investment analysts have rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $21.25.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded up $0.79 during trading on Friday, reaching $8.31. 4,234,901 shares of the company's stock were exchanged, compared to its average volume of 2,914,198. TG Therapeutics has a fifty-two week low of $3.48 and a fifty-two week high of $35.94. The business has a 50 day moving average price of $5.47 and a 200-day moving average price of $7.48. The company has a debt-to-equity ratio of 0.53, a current ratio of 4.68 and a quick ratio of 4.43.

TG Therapeutics (NASDAQ:TGTX - Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.04. The firm had revenue of $2.02 million for the quarter, compared to analysts' expectations of $1.54 million. TG Therapeutics had a negative return on equity of 136.07% and a negative net margin of 4,144.49%. As a group, equities research analysts anticipate that TG Therapeutics will post -1.77 earnings per share for the current year.

Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Stock News Headlines

Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $21.25
TG Therapeutics (NASDAQ:TGTX) Shares Down 5.3%
TG Therapeutics (NASDAQ:TGTX) Shares Down 2.7%
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Company Calendar

Last Earnings
11/04/2021
Today
8/14/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TGTX
Employees
286
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.25
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+155.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-348,100,000.00
Net Margins
-4,144.49%
Pretax Margin
-4,144.52%

Debt

Sales & Book Value

Annual Sales
$6.69 million
Book Value
$0.89 per share

Miscellaneous

Free Float
132,780,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
2.28














TGTX Stock - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 2 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TGTX, but not buy additional shares or sell existing shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price forecast for 2022?

6 Wall Street research analysts have issued 12 month price objectives for TG Therapeutics' stock. Their TGTX share price forecasts range from $13.00 to $36.00. On average, they predict the company's share price to reach $21.25 in the next year. This suggests a possible upside of 155.7% from the stock's current price.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How have TGTX shares performed in 2022?

TG Therapeutics' stock was trading at $19.00 on January 1st, 2022. Since then, TGTX shares have decreased by 56.3% and is now trading at $8.31.
View the best growth stocks for 2022 here
.

When is TG Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.09. The biopharmaceutical company had revenue of $2.03 million for the quarter, compared to the consensus estimate of $3.23 million. TG Therapeutics had a negative net margin of 4,144.49% and a negative trailing twelve-month return on equity of 136.07%. During the same period in the prior year, the company posted ($0.73) earnings per share.

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (5.54%), Assenagon Asset Management S.A. (1.45%), Northern Trust Corp (0.86%), Renaissance Technologies LLC (0.82%), Eagle Asset Management Inc. (0.49%) and Rafferty Asset Management LLC (0.42%). Insiders that own company stock include Michael S Weiss, Ra Capital Management, LP, Sean A Power, William James Kennedy and Yann Echelard.
View institutional ownership trends
.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $8.31.

How much money does TG Therapeutics make?

TG Therapeutics (NASDAQ:TGTX) has a market capitalization of $1.21 billion and generates $6.69 million in revenue each year. The biopharmaceutical company earns $-348,100,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

How many employees does TG Therapeutics have?

The company employs 286 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.tgtherapeutics.com. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at ir@tgtxinc.com, or via fax at 212-554-4531.

This page (NASDAQ:TGTX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.